About Company
Advance to the Mainland China market
- Renewed ISO 13485 Certification (ISO 13485:2016)
About Company
2019
BOBC announced the development of Collagen Lens, a protective corneal shield derived from the company’s proprietary Biocornea platform.
BOBC and Aeon Astron Europe B.V. renewed their respective ISO 13485 Certification (ISO 13485:2016).
BOBC received a US invention patent for a novel fish skin-based biomaterial.
2018
Subsidiary Aeon Astron Europe B.V. passed an on-site inspection by the US Food and Drug Administration (FDA) successfully.
BOBC received Taiwan FDA approval for the ologen® Collagen Matrix.
BOBC received a European invention patent for technology advances made in the field of biomaterials.
BOBC received a Korea invention patent for technology advances made in the field of biomaterials.
2017
BOBC received a Japan invention patent for technology advances made in the field of biomaterials.
BOBC became GMP (Taiwan) certified to produce the Biocornea on top of existing product lines.
BOBC received an Indonesia invention patent for technology advances made in the field of biomaterials.
2016
BOBC received a Taiwan invention patent for technology advances made in the field of ophthalmology.
BOBC received an international branding subsidy of NTD $2.5 Million from the Department of Economic Development, Taipei City Government.
Indian subsidiary, Aeon Ajanta India Pvt. Ltd., officially launched.
The Biocornea clinical trial at the University Hospital of the University of Cologne (Uniklinik Köln, Universität zu Köln) began.
BOBC received a German invention patent for technology advances made in the field of ophthalmology.
2015
BOBC obtained certified High Tech Industry status from the Taiwan Industrial Development Bureau, Ministry of Economic Affairs.
2014
ologen® Collagen Matrix vs. MMC in Trabeculectomy- A Five-Year report at 2014 WOC, Tokyo.
2013
ologen® Collagen Matrix attained health approval in Peru.
ologen® Collagen Matrix for congenital glaucoma: presentation at 2013 WGC, Vancouver.
ologen® Collagen Matrix for congenital glaucoma: case report at 2013 SOE Congress, Copenhagen.
ologen® Collagen Matrix attained health approval in Mexico.
The number of ologen Collagen Matrix’s SCI/SCIE publications reaches fifteen (15).
2012
ologen® Collagen Matrix attained health approval in Vietnam.
ologen® Collagen Matrix attained health approval in Saudi Arabia.
Founding of the Network of Excellence in Corneal Regeneration (NEXCR).
2011
Aeon Astron Europe B.V. received grant EURO 500,000 from AgentschapNL, Dept. of Economic Affairs of the Netherlands.
Aeon Astron Europe B.V. and Aeon Astron USA became 100% reinvested subsidiaries of BOBC.
ologen® Collagen Matrix is reimbursed in Tunisia.
ologen® Collagen Matrix attained health approval in Egypt.
Aeon Astron Europe B.V. is the Glaucoma Industry member of WGA.
2010
ologen® Collagen Matrix attained health approval in Jordan.
ologen® Collagen Matrix obtained CMDCAS certificate.
ologen® Collagen Matrix is reimbursed by the Medicare System in Sweden.
ologen® Collagen Matrix is reimbursed by the General Insurance Agency in Czech.
2009
ologen® and Aongen® received US FDA 510K clearance letter.
2008
The brand oculusgen has been changed to ologen.
Collagen Matrix and Bandage Lens CE certificates attained.
Aeon Astron Europe B.V. ISO 13485 certificate was obtained.
Aeon Astron Europe B.V. was established.
2007
BOBC attained ISO 13485:2003 certificate.
Body Organ Biomedical Corporation was established.
Tel:+886 2 2659 7698
E-mail:contactus@aeonastron.com
Add:5F., No. 322, Sec. 1, Neihu Rd., Neihu Dist., Taipei City 114, Taiwan (R.O.C.)